Development of novel anti-cancer agents targeting cancer stem cells
| Project/Area Number |
26460201
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
Ikeda Ryuji 鹿児島大学, 医歯学域附属病院, 准教授 (50398278)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
武田 泰生 鹿児島大学, 医歯学域附属病院, 教授 (60245462)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 抗がん剤耐性 / がん幹細胞 / ABCトランスポーター / Cancer stem-like cells / Akt シグナル / sphere形成 / 抗がん薬耐性 / S100A16 |
|---|
| Outline of Final Research Achievements |
Mechanisms of anti-cancer drug resistance include various factors, such as the increased drug efflux by cancer cells, activation of survival signaling pathways by growth factors. In addition, cancer stem cells have been found in tumors. Cancer stem cells are characterized by the overexpression of ABC transporters, such as P-glycoproteins and breast cancer resistance protein. The expressions of the transporters partially explain the multidrug resistance of cancer. Novel anti-cancer agents and therapies have been developed every year. Besides conventional anti-cancer agents, molecular target drugs for cancer play important roles in the management of cancer therapy. However, some tumors become resistant to these drugs. Medical practice and research based on more scientific evidence are demanded to provide appropriate and high-quality treatments for patients.
|
Report
(4 results)
Research Products
(30 results)
-
[Journal Article] Thymidine Catabolism as a Metabolic Strategy for Cancer Survival2017
Author(s)
Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI
-
Journal Title
Cell Rep
Volume: 19
Issue: 7
Pages: 1313-1321
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma.2015
Author(s)
Desaki R, Sawada G, Okumura H, Ikeda R, Tanabe K, Komatsu H, Mimori K, Mori M, Kita Y, Uchikado Y, Arigami T, Uenosono Y, Owaki T, Ishigami S, Natsugoe S.
-
Journal Title
Ann Surg Oncol.
Volume: Epub
Issue: 2
Pages: 586-593
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors2015
Author(s)
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra, Pérez-Torrasj, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo
-
Journal Title
Journal of Pharmaceutical Sciences
Volume: 127
Pages: 319-325
Related Report
Peer Reviewed
-
[Journal Article] Green tea catechin, epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression2014
Author(s)
Jun-Ichiro Sonoda, Ryuji Ikeda, Yasutaka Baba, Keiko Narumi, Akio Kawachi, Erisa Tomishige, Kazuya Nishihara, Yasuo Takeda, Katsushi Yamada, Keizo Sato, Toshiro Motoya
-
Journal Title
Experimental and Therapeutic Medicine
Volume: 8
Pages: 59-63
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
